Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 May;61(5):513-20.
doi: 10.1111/j.1365-2125.2006.02611.x.

The implications of a growing evidence base for drug use in elderly patients. Part 3. Beta-adrenoceptor blockers in heart failure and thrombolytics in acute myocardial infarction

A A Mangoni  1 , S H D Jackson
Affiliations
Review

The implications of a growing evidence base for drug use in elderly patients. Part 3. Beta-adrenoceptor blockers in heart failure and thrombolytics in acute myocardial infarction

A A Mangoni et al. Br J Clin Pharmacol. 2006 May.

Abstract

Beta-adrenoceptor blockers and thrombolytic agents are of established value in the pharmacological management of heart failure and ST-elevation myocardial infarction, respectively. However, there is uncertainty as to whether these therapeutic strategies can be safely and effectively adopted in elderly patients with comorbidities, particularly in old-old individuals. This review focuses on these trials and the age-related efficacy and safety of these drugs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Age distribution of trials on β-adrenoceptor blockers in elderly patients. M, mean age; SD, standard deviation; Max, maximum age
Figure 2
Figure 2
Age distribution of trials on thrombolytics in elderly patients. M, mean age; SD, standard deviation; Max, maximum age; ¶, M and SD not available
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. The Cardiac Insufficiency Bisoprolol Study II, (CIBIS-II) A randomised trial. Lancet. 1999;353:9–13. - PubMed
    1. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8. - PubMed
    1. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Effect of metoprolol CR/XL in chronic heart failure. Lancet. 1999;353:2001–7. - PubMed
    1. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295–302. - PubMed
    1. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527–60. - PubMed

Substances